622 related articles for article (PubMed ID: 28640702)
1. Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
van den Bent MJ; Smits M; Kros JM; Chang SM
J Clin Oncol; 2017 Jul; 35(21):2394-2401. PubMed ID: 28640702
[TBL] [Abstract][Full Text] [Related]
2. Grade II and III Oligodendroglioma and Astrocytoma.
van den Bent MJ; Chang SM
Neurol Clin; 2018 Aug; 36(3):467-484. PubMed ID: 30072066
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.
Ruff MW; Uhm J
Curr Treat Options Oncol; 2018 Oct; 19(12):61. PubMed ID: 30361986
[TBL] [Abstract][Full Text] [Related]
4. Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ; Bromberg JE; Buckner J
Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic oligodendroglioma and oligoastrocytoma.
van den Bent MJ
Neurol Clin; 2007 Nov; 25(4):1089-109, ix-x. PubMed ID: 17964027
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
7. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
8. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA; Messersmith H; Gatson NT; Hottinger AF; Lassman A; Morton J; Ney D; Nghiemphu PL; Olar A; Olson J; Perry J; Portnow J; Schiff D; Shannon A; Shih HA; Strowd R; van den Bent M; Ziu M; Blakeley J
J Clin Oncol; 2022 Feb; 40(4):403-426. PubMed ID: 34898238
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
10. Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma.
Khan KA; Abbasi AN; Ali N
J Coll Physicians Surg Pak; 2014 Dec; 24(12):935-9. PubMed ID: 25523732
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
McNamara MG; Jiang H; Lim-Fat MJ; Sahebjam S; Kiehl TR; Karamchandani J; Coire C; Chung C; Millar BA; Laperriere N; Mason WP
Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
[TBL] [Abstract][Full Text] [Related]
12. Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted).
Anderson MD; Gilbert MR
J Natl Compr Canc Netw; 2014 May; 12(5):665-72. PubMed ID: 24812135
[TBL] [Abstract][Full Text] [Related]
13. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic astrocytoma.
Grimm SA; Chamberlain MC
CNS Oncol; 2016 Jul; 5(3):145-57. PubMed ID: 27230974
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
16. Current Considerations in the Treatment of Grade 3 Gliomas.
Jo J; Schiff D
Curr Treat Options Oncol; 2022 Sep; 23(9):1219-1232. PubMed ID: 35913658
[TBL] [Abstract][Full Text] [Related]
17. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Franceschi E; Tosoni A; De Biase D; Lamberti G; Danieli D; Pizzolitto S; Zunarelli E; Visani M; Di Oto E; Mura A; Minichillo S; Scafati C; Asioli S; Paccapelo A; Bartolini S; Brandes AA
Oncologist; 2019 May; 24(5):664-670. PubMed ID: 30777895
[TBL] [Abstract][Full Text] [Related]
18. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
19. [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
Wick W; Weller M
Nervenarzt; 2010 Aug; 81(8):928-30, 932-5. PubMed ID: 20635074
[TBL] [Abstract][Full Text] [Related]
20. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]